Bayer AG (BAYRY)
10.19
+0.04
(+0.39%)
USD |
OTCM |
Jun 09, 16:00
Bayer Enterprise Value : 78.38B for June 9, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 09, 2026 | 78.38B |
| June 08, 2026 | 78.23B |
| June 05, 2026 | 78.82B |
| June 04, 2026 | 78.74B |
| June 03, 2026 | 77.40B |
| June 02, 2026 | 77.17B |
| June 01, 2026 | 78.23B |
| May 29, 2026 | 79.80B |
| May 28, 2026 | 81.33B |
| May 27, 2026 | 81.61B |
| May 26, 2026 | 81.25B |
| May 22, 2026 | 82.00B |
| May 21, 2026 | 82.67B |
| May 20, 2026 | 82.90B |
| May 19, 2026 | 81.76B |
| May 18, 2026 | 81.65B |
| May 15, 2026 | 81.17B |
| May 14, 2026 | 81.69B |
| May 13, 2026 | 81.80B |
| May 12, 2026 | 82.39B |
| May 11, 2026 | 81.10B |
| May 08, 2026 | 81.02B |
| May 07, 2026 | 81.04B |
| May 06, 2026 | 82.51B |
| May 05, 2026 | 81.45B |
| Date | Value |
|---|---|
| May 04, 2026 | 80.90B |
| May 01, 2026 | 82.00B |
| April 30, 2026 | 82.24B |
| April 29, 2026 | 79.76B |
| April 28, 2026 | 80.00B |
| April 27, 2026 | 80.39B |
| April 24, 2026 | 82.35B |
| April 23, 2026 | 83.89B |
| April 22, 2026 | 84.48B |
| April 21, 2026 | 83.89B |
| April 20, 2026 | 85.97B |
| April 17, 2026 | 85.58B |
| April 16, 2026 | 84.71B |
| April 15, 2026 | 85.34B |
| April 14, 2026 | 85.10B |
| April 13, 2026 | 85.50B |
| April 10, 2026 | 84.51B |
| April 09, 2026 | 84.67B |
| April 08, 2026 | 84.36B |
| April 07, 2026 | 83.34B |
| April 06, 2026 | 83.34B |
| April 02, 2026 | 82.59B |
| April 01, 2026 | 83.93B |
| March 31, 2026 | 83.45B |
| March 30, 2026 | 78.50B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| SenesTech, Inc. | 5.000M |
| Dermapharm Holding SE | 4.110B |
| Johnson & Johnson | 603.30B |
| Pfizer Inc. | 198.15B |
| AstraZeneca PLC | 595.23B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 3.237B |
| Revenue (Quarterly) | 15.68B |
| Total Expenses (Quarterly) | 12.45B |
| EPS Diluted (Quarterly) | 0.8226 |
| Gross Profit Margin (Quarterly) | 60.97% |
| Profit Margin (Quarterly) | 20.64% |
| Earnings Yield | -6.22% |
| Operating Earnings Yield | 20.16% |
| Normalized Earnings Yield | 5.280 |